IP Library Granted Patent US 8,450,506
Granted Patent B2
US 8,450,506 · App. 13/397,245 · Granted May 28, 2013

Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,450,506
App. No.
13/397,245
Granted
May 28, 2013
Kind
B2
Abstract

The present invention relates to compounds of formula (I), where R 1 and R 2 , which may be identical or different, are selected from the group comprising H, C n H 2n-1 , a linear or branched alkyl group having 1 to 6 carbons, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R 3 is —CO—CH 3 , —NHOH, —OH, or —OR 6 where R 6 is a linear or branched alkyl group having 1 to 6 carbon atoms; R4 is H, linear or branched alkyl group having from 1 to 6 atoms, phenyl, benzyl, —CF 3 or CF 2 CF 3 , vinyl or allyl; R 5 , R 7 , R 8 are hydrogen atoms; or R 3 and R 4 , R 4 and R 5 , or R 7 and R 8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O, and use thereof in the medical field.

Claims (20)

1. A compound of the general formula (I)

in which

R 1 and R 2 , which may be identical or different, are selected from the group consisting of H, a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aliphatic ring with 5 or 6 atoms;

R 5 , R 7 , R 8 are each independently selected from hydrogen atoms, or —NR 1 R 2 ;

R 3 and R 4 together form an aliphatic ring with 1 to 2 heteroatoms selected independently from N or O;

or a salt thereof.

2. The compound of claim 1 , wherein R 1 and R 2 are each independently selected from the group consisting of: —CH 3 , —C 2 H 5 , isopropyl, or propyl.

3. The compound of claim 1 , wherein R 1 and R 2 , are both H.

4. The compound of claim 1 , represented by:

5. The compound of claim 1 , represented by:

6. A pharmaceutical composition comprising a compound of claim 1 , in combination with one or more pharmaceutically acceptable excipients or adjuvants.

7. A method of treating colon tumours in a human or animal in need thereof, comprising administering to the human or animal a compound according to claim 1 .

8. A method of treating Crohn's disease or ulcerative rectocolitis in a human or animal in need thereof, comprising administering to the human or animal a compound according to claim 1 .

9. A method of treating Crohn's disease, ulcerative rectocolitis or colon cancer in a human or animal in need thereof, comprising administering to the human or animal a compound selected from the group consisting of:

1,2,3,4-tetrahydro-6-hydroxyquinoline-5-carboxylic acid;

6-methoxyquinoline-5-carboxylic acid;

6-methoxy-1,2,3,4-tetrahydroquinoline-5-carboxylic acid,

4-diispropylaminosalicylic acid,

and salts thereof.

10. A method of treating Crohn's disease or ulcerative rectocolitis in a human or animal in need thereof, comprising administering to the human or animal a compound represented by:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2015
From: NACCARI, GIANCARLO; BARONI, SERGIO
To: GIULIANI INTERNATIONAL LIMITED
Reel/Frame 035480/0341 →
CHANGE OF NAME Recorded Nov 14, 2012
From: GIULIANI INTERNATIONAL LIMITED
To: NOGRA PHARMA LIMITED
Reel/Frame 029295/0861 →